Observational studyBMC pulmonary medicine2026
Association between albumin-corrected anion gap and 28-day mortality in critically ill patients with pneumonia in the intensive care unit: evidence from the medical information mart for intensive care IV database.
Observational study in BMC pulmonary medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundThe albumin-corrected anion gap (ACAG) has been shown to be associated with prognosis in critically ill patients. However, few studies have investigated the association between ACAG and 28-day mortality in critically ill patients with pneumonia. We hypothesized that the initial ACAG level could predict 28-day mortality risk in critically ill patients with pneumonia.
methodsThis retrospective observational cohort study used the Medical Information Mart for Intensive Care-IV database. Demographic characteristics, vital signs, laboratory parameters, comorbidities, and severity scores were extracted from the first 24 h of intensive care unit admission. Kaplan–Meier curves with log-rank tests were generated to visualize unadjusted survival differences according to ACAG tertiles. Multivariable Cox proportional hazards regression models employing restricted cubic splines (four knots) were used to evaluate the nonlinear association between serum ACAG concentration and 28-day mortality. Effect modification was assessed through interaction and stratified analyses across prespecified subgroups (age, sex, and comorbidity burden).
resultsAmong 4,630 intensive care unit patients with pneumonia, 1,364 (29.5%) died by day 28. Each 1-mmol/L increment in ACAG independently predicted high mortality (adjusted hazard ratio [HR] 1.02, 95% confidence interval [CI] 1.01–1.03; p < 0.001), exhibiting dose dependency (10-mmol/L increase: HR 1.24, 95% CI 1.11–1.38). The highest ACAG tertile demonstrated a 19% greater mortality risk versus the lowest (HR 1.19, 95% CI 1.01–1.39), whereas the intermediate tertile showed a non-significant association (HR 1.07, 95% CI 0.92–1.24). Restricted cubic splines confirmed a monotonic dose–response relation (non-linearity, p = 0.423), with Kaplan–Meier curves revealing progressively worse survival across the ascending tertiles (log-rank p < 0.0001). Subgroup analyses indicated consistent effects across strata, with sepsis status as the sole significant modifier (interaction p = 0.025).
conclusionIn critically ill pneumonia patients, ACAG may be a practical prognostic biomarker, and prospective studies with external validation are recommended.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.